Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|January 16, 2014
Emerging Treatment Options for Patients With Kidney Cancer
Author(s)James J. Hsieh, MD, PhD
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
Advertisement
Clinical Pearls
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
- New emerging treatment options are all trial-based
- There are newer antiangiogenic agents that are just as efficacious but generate less toxicity
- Researchers and oncologists are excited about immunotherapy for the treatment of kidney cancer
- New immunotherapies are similar to interleukin-2 and interferon but are more effective, more specific, and less toxic
Advertisement
Related to this article
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Oncologists discuss LITESPARK-011 findings and the potential role of belzutifan plus lenvatinib in second-line advanced renal cell carcinoma treatment and sequencing.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, manufacturing controls, lot release assays, and monitoring.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5